Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: J Hepatol. 2021 Sep 30;76(2):383–393. doi: 10.1016/j.jhep.2021.09.021

Figure 1. T39 interacts with phosphorylated pRb.

Figure 1.

(A) Hepatic Pnpla3 expression in mice treated with T39 GalNac ASO and fed (HFSC) diet for various durations. N= 8 per group, males, **p<0.01 by two-tailed nonparametric t-test corrected for multiple comparisons. (B) Co-immunoprecipitation of wild type T39 and wild type Rb, (C) co-immunoprecipitation of T39 and pRb N-terminus, (D) Co-immunoprecipitation of pRb N-terminus with T39 containing mutations surrounding the hydrophobic pocket and in the N-terminus with the structural model shown on top (colored residues are red = D483, green = F495, blue = S509, and yellow = F515), (E) Co-immunoprecipitation of T39 and phosphorylation-deficient pRb, and (F) co-immunoprecipitation of T39 and pRb with palbociclib in subconfluent HEK293A cells. (G) Hepatic lipogenic gene expression in refed mice fed the HFSC diet for 14 weeks, then administered palbociclib, n=5 per group, **p<0.05, **p<0.001 by two-way ANOVA with Sidak’s multiple comparisons test.